MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

39.85 -0.72 (-1.77%)
Streaming Delayed Price Updated: 3:00 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Veracyte Inc. (NASDAQ:VCYT) Emerges as a Prime Affordable Growth Candidate ↗
Via Chartmill
News headline image
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025... 
Via MarketMinute
Topics Artificial Intelligence Death
News headline image
Veracyte Inc (NASDAQ:VCYT) Emerges as a Top Affordable Growth Stock ↗
Veracyte (VCYT) exemplifies the GARP strategy, offering strong growth, a reasonable industry price, and a solid debt-free financial foundation. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT): A GARP Stock With Strong Growth and a Reasonable Price ↗
Veracyte (VCYT) exemplifies GARP investing with strong cancer diagnostic growth, reasonable valuation vs. biotech peers, and a debt-free financial foundation. 
Via Chartmill
News headline image
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Biotech ↗
Veracyte (VCYT) offers affordable growth with strong earnings, a solid balance sheet, and reasonable valuation in the biotech sector. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT) Presents a Strong Growth and Breakout Opportunity ↗
Veracyte (VCYT) stock analysis shows strong growth potential with 20% revenue growth, zero debt, and a bullish technical setup for a breakout. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT): An Affordable Growth Candidate in Cancer Diagnostics ↗
Veracyte (VCYT) offers affordable growth with strong revenue & earnings expansion, a solid debt-free balance sheet, and reasonable valuation for the biotech sector. 
Via Chartmill
News headline image
Veracyte Inc (NASDAQ:VCYT) Emerges as a Strong Value Pick with Solid Fundamentals and Growth Potential ↗
Veracyte (VCYT) emerges as a potential value stock with strong valuation, profitability, and growth metrics in the biotech sector, backed by solid financial health and cash flow potential. 
Via Chartmill
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts ↗
 
Via Benzinga
News headline image
Veracyte (VCYT) Q2 Revenue Jumps 14% ↗
Via The Motley Fool
News headline image
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics ↗
Ark Invest traded in VCYT, IRDM, CRSP, KTOS, ABSI, VEEV, ADPT, and GH. Mainly focused on healthcare innovation. 
Via Benzinga
News headline image
VERACYTE INC (NASDAQ:VCYT) – An Undervalued Stock with Strong Fundamentals ↗
VERACYTE INC (NASDAQ:VCYT) is an undervalued biotech stock with strong financial health, solid profitability, and impressive growth prospects, making it a candidate for value investors. 
Via Chartmill
News headline image
Cathie Wood's Ark Invest Adds Airbnb, AMD, Shopify To Portfolio, Slashes Stake In Circle Internet ↗
 
Via Benzinga
News headline image
Cathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D Systems ↗
Ark Invest made notable trades on Friday, including purchasing shares of Veracyte Inc. and selling shares of 3D Systems Corp. 
Via Benzinga
News headline image
VERACYTE INC (NASDAQ:VCYT) – A Promising Affordable Growth Stock in Biotechnology ↗
VERACYTE INC (NASDAQ:VCYT) is a biotechnology stock with strong growth, solid profitability, and reasonable valuation, making it an attractive pick for investors seeking affordable growth... 
Via Chartmill
News headline image
Breaking Down Veracyte: 7 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch ↗
Veracyte Inc (NASDAQ:VCYT) – An Affordable Growth Stock to Watch 
Via Chartmill
News headline image
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms ↗
ARK Invest made significant trades in NTLA, META, VCYT, SYM, BIDU, and PATH. These moves come amidst changes in stock prices. Read more for full details. 
Via Benzinga
News headline image
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. ↗
A revolution in oncology could help cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences. 
Via Investor's Business Daily
News headline image
Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability. ↗
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable. ↗
NASDAQ:VCYT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
News headline image
5 Analysts Assess Veracyte: What You Need To Know ↗
 
Via Benzinga
News headline image
Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade ↗
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50. 
Via Benzinga
News headline image
VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank. ↗
Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing... 
Via Chartmill
News headline image
Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive ↗
Veracyte topped Q4 earnings and revenue estimates as testing volume grew. The company is evaluating options for its French unit. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story